Genmab GMAB Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$53.63 up $0.89, 1.69% at close Nov 6
Last close · Previous close $52.74
- Market cap
- At the Nov 6 close
- P/E ratio
- 45.76On last 12 months’ EPS
- Diluted EPS
- $1.17Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$53.63up $0.89, 1.69%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$52.74Nov 5
- Volume7.83MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume6.12MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $23.62 to $59.97; now $53.63
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
GMAB beat the S&P 500 in 5 of 7 periods.
| Period | GMAB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | GMAB: up 41.9% S&P 500: down 5.6% | GMAB beat the S&P 500 by 47.5 percentage points Beat |
| 3M | GMAB: up 79.8% S&P 500: down 4.1% | GMAB beat the S&P 500 by 83.9 percentage points Beat |
| YTD | GMAB: up 74.1% S&P 500: up 8.7% | GMAB beat the S&P 500 by 65.4 percentage points Beat |
| 1Y | GMAB: up 86.0% S&P 500: up 10.9% | GMAB beat the S&P 500 by 75.1 percentage points Beat |
| Long term | ||
| 3Y | GMAB: up 85.9% S&P 500: up 75.0% +23.0% vs +20.5% a year | GMAB beat the S&P 500 by 10.9 percentage points Beat |
| 5Y | GMAB: up 15.4% S&P 500: up 67.8% +2.9% vs +10.9% a year | GMAB trailed the S&P 500 by 52.4 percentage points Trailed |
| 10Y | GMAB: up 204.6% S&P 500: up 313.1% +11.8% vs +15.2% a year | GMAB trailed the S&P 500 by 108.5 percentage points Trailed |
$10,000 invested in GMAB 10 years ago (Nov 4, 2016) would be worth about $30,465 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
GMAB beat the S&P 500 in 5 of 7 periods.
| Period | GMAB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | GMAB: up 41.9% S&P 500: down 5.6% | GMAB beat the S&P 500 by 47.5 percentage points Beat |
| 3M | GMAB: up 79.8% S&P 500: down 4.3% | GMAB beat the S&P 500 by 84.1 percentage points Beat |
| YTD | GMAB: up 74.1% S&P 500: up 7.8% | GMAB beat the S&P 500 by 66.3 percentage points Beat |
| 1Y | GMAB: up 86.0% S&P 500: up 9.7% | GMAB beat the S&P 500 by 76.3 percentage points Beat |
| Long term | ||
| 3Y | GMAB: up 85.9% S&P 500: up 68.8% +23.0% vs +19.1% a year | GMAB beat the S&P 500 by 17.1 percentage points Beat |
| 5Y | GMAB: up 15.4% S&P 500: up 56.9% +2.9% vs +9.4% a year | GMAB trailed the S&P 500 by 41.5 percentage points Trailed |
| 10Y | GMAB: up 204.6% S&P 500: up 252.6% +11.8% vs +13.4% a year | GMAB trailed the S&P 500 by 48.0 percentage points Trailed |
$10,000 invested in GMAB 10 years ago (Nov 4, 2016) would be worth about $30,465 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$57.29
Closing high on . Now 6.4% below that record.
Split-adjusted daily closes since Jun 1, 2009.
Stock splits
1
5-for-1 on . One share bought before the first split is 5 shares today.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $4.30Bup 19.8%
- Net income
- $729.00Mdown 50.9%
- Diluted EPS
- $1.17down 50.1%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $923.00M | $552.00M | $0.85 |
| Q1 FY25 (Mar 31, 2025) | $715.00M | $195.00M | $0.31 |
| Q2 FY25 (Jun 30, 2025) | $925.00M | $336.00M | $0.54 |
| Q3 FY25 (Sep 30, 2025) | $1.02B | $401.00M | $0.65 |
| Q4 FY25 (Dec 31, 2025) | $1.06B | $31.00M | $0.05 |
| Q1 FY26 (Mar 31, 2026) | $896.00M | $53.00M | $0.08 |
| Q2 FY26 (Jun 30, 2026) | $1.16B | $303.00M | $0.49 |
| Q3 FY26 (Sep 30, 2026) | $1.19B | $342.00M | $0.55 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $1.18B | $413.98M | $0.63 |
| FY22 (Dec 31, 2022) | $2.03B | $750.00M | $1.14 |
| FY23 (Dec 31, 2023) | $2.39B | $631.00M | $0.96 |
| FY24 (Dec 31, 2024) | $3.12B | $1.13B | $1.75 |
| FY25 (Dec 31, 2025) | $3.72B | $963.00M | $1.54 |
Margins
- Gross 92.6%
- Operating 24.3%
- Net 17.0%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $843.00MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$875.00MLast 12 months
- Capital spending$32.00MLast 12 months
- 19.6%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $96.00MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $1.90BAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$5.20BAs of Sep 30, 2026
- Net debt$3.30BAs of Sep 30, 2026
- 2.45As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.82As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✓Share count didn’t rise: passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 12.2%Last 12 months
Over the last 12 months, Genmab’s net income was 12.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 5.8%Last 12 months
Over the last 12 months, Genmab’s net income was 5.8% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Genmab
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO ® ) antibody medicines. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Denmark
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
GMAB news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
GMAB stock FAQ
What is GMAB stock’s price today?
Genmab (GMAB) traded at $53.63 at the close on , up $0.89 (1.69%) from the previous close of $52.74. Over the past 52 weeks it has traded between $23.62 and $59.97.
If you invested $1,000 in GMAB 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in GMAB on would be worth about $3,046 at the close on , a total return of +204.6%. The same $1,000 would be worth $1,154 if invested five years ago and $1,860 if invested one year ago. Past performance doesn’t predict future returns.
What is GMAB’s P/E ratio?
GMAB trades at 45.8 times its diluted earnings over the four quarters to ($1.17 per share), at the close. (How the P/E ratio works.)
How much revenue does Genmab make?
Genmab reported $4.3 billion of revenue over the four quarters to , up 19.8% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $1.2 billion, up 16.1% from a year earlier.
Is Genmab profitable?
Yes. Genmab earned $729.0 million of net income over the four quarters to , a net margin of 17.0%, and its operating margin was 24.3% (what margins tell you).
What are GMAB’s earnings per share?
GMAB’s diluted earnings per share were $1.17 over the four quarters to , compared with $2.35 in the twelve months before. The latest quarter (Q3 FY26) brought $0.55 per share, against $0.65 a year earlier (how EPS works).
Does GMAB pay a dividend?
Genmab hasn’t paid a dividend in the last twelve months.
What is GMAB’s 52-week high and low?
Over the past 52 weeks GMAB has traded as low as $23.62 and as high as $59.97. At $53.63 at the close on , it is 10.6% below that high and 127.1% above the low.
What is GMAB’s all-time high?
GMAB’s highest closing price was $57.29 on , adjusted for stock splits. At $53.63 at the close on , it is 6.4% below that record.
Has GMAB stock ever split?
Yes, once: 5-for-1 on . One share bought before the first split would be 5 shares today.
How has GMAB stock performed?
Including dividends and measured to the close on , GMAB has returned +74.1% so far this year and +86.0% over the past year, and +15.4% over five years (+2.9% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Genmab in?
Genmab is in the Healthcare sector and the Biotechnology industry, and is headquartered in Denmark.
What exchange does GMAB trade on?
Genmab trades on the Nasdaq under the ticker symbol GMAB. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.